{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:15:37Z","timestamp":1762899337928},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T00:00:00Z","timestamp":1480636800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00535-016-1290-1","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T10:04:39Z","timestamp":1480673079000},"page":"845-854","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b"],"prefix":"10.1007","volume":"52","author":[{"name":"The Kyushu University Liver Disease Study (KULDS) Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Dohmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeaki","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,2]]},"reference":[{"key":"1290_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000252782","volume":"53","author":"H Chung","year":"2010","unstructured":"Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50\u00a0years in Japan. Intervirology. 2010;53:39\u201343.","journal-title":"Intervirology"},{"key":"1290_CR2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346\u201355.","journal-title":"Ann Intern Med"},{"key":"1290_CR3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"T Poynard","year":"2002","unstructured":"Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303\u201313.","journal-title":"Gastroenterology"},{"key":"1290_CR4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1440-1746.2008.05319.x","volume":"23","author":"N Furusyo","year":"2008","unstructured":"Furusyo N, Kajiwara E, Takahashi K, et al. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol. 2008;23:1094\u2013104.","journal-title":"J Gastroenterol Hepatol"},{"key":"1290_CR5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1440-1746.2011.06965.x","volume":"27","author":"E Ogawa","year":"2012","unstructured":"Ogawa E, Furusyo N, Kajiwara E, et al. Evaluation of the adverse effect of premature discontinuation of pegylated interferon \u03b1-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol. 2012;27:1233\u201340.","journal-title":"J Gastroenterol Hepatol"},{"key":"1290_CR6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483\u201393.","journal-title":"N Engl J Med"},{"key":"1290_CR7","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879\u201388.","journal-title":"N Engl J Med"},{"key":"1290_CR8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645\u201353.","journal-title":"Lancet Infect Dis"},{"key":"1290_CR9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.28625","volume":"64","author":"LI Backus","year":"2016","unstructured":"Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness of ledipasvir\/sofosbuvir in 4365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64:405\u201314.","journal-title":"Hepatology"},{"key":"1290_CR10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","volume":"151","author":"GN Ioannou","year":"2016","unstructured":"Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology. 2016;151:457\u201371.","journal-title":"Gastroenterology"},{"key":"1290_CR11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.antiviral.2009.04.002","volume":"83","author":"E Ogawa","year":"2009","unstructured":"Ogawa E, Furusyo N, Toyoda K, et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009;83:127\u201334.","journal-title":"Antiviral Res"},{"key":"1290_CR12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32\u20136.","journal-title":"Hepatology"},{"key":"1290_CR13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"1290_CR14","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/jgh.13016","volume":"30","author":"E Ogawa","year":"2015","unstructured":"Ogawa E, Furusyo N, Kajiwara E, et al. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol. 2015;30:1759\u201367.","journal-title":"J Gastroenterol Hepatol"},{"key":"1290_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12738","author":"E Ogawa","year":"2016","unstructured":"Ogawa E, Furusyo N, Yamashita N, et al. Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis. Hepatol Res. 2016. doi:\n                        10.1111\/hepr.12738\n                        \n                    .","journal-title":"Hepatol Res"},{"key":"1290_CR16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2016.10.012","volume":"136","author":"E Ogawa","year":"2016","unstructured":"Ogawa E, Furusyo N, Nomura H, et al. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Res. 2016;136:37\u201344.","journal-title":"Antiviral Res"},{"unstructured":"HCV Guidance: recommendations for testing, managing, and treating hepatitis C. AASLD and IDSA. \n                        http:\/\/www.hcvguidelines.org\n                        \n                    . Accessed 9 Sept 2016.","key":"1290_CR17"},{"key":"1290_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. EASL recommendation on treatment of hepatitis C 2016. J Hepatol. 2016. doi:\n                        10.1016\/j.jhep.2016.09.001\n                        \n                    .","journal-title":"J Hepatol"},{"key":"1290_CR19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","volume":"151","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151:501\u201312.","journal-title":"Gastroenterology"},{"key":"1290_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12549","author":"M Mizokami","year":"2016","unstructured":"Mizokami M, Dvory-Sobol H, Izumi N, et al. Resistance analyses of Japanese hepatitis C-infected patients receiving sofosbuvir or ledipasvir\/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat. 2016. doi:\n                        10.1111\/jvh.12549\n                        \n                    .","journal-title":"J Viral Hepat"},{"key":"1290_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28782","author":"EB Tapper","year":"2016","unstructured":"Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. Hepatology. 2016. doi:\n                        10.1002\/hep.28782\n                        \n                    .","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-016-1290-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T21:10:08Z","timestamp":1501017008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-016-1290-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1007\/s00535-016-1290-1","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}